PF-08634404 is named as a drug or biological intervention in 10 clinical trials in our USA, China and India trial registers, 10 of which are recruiting. The lead sponsor is Pfizer. Registered phases: Phase 1/2, Phase 2, Phase 2/3 and Phase 3. Conditions studied include Lung Neoplasms; Non-Small Cell Lung Cancer; Carcinoma.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Lung Neoplasms | 2 |
| Non-Small Cell Lung Cancer | 2 |
| Carcinoma | 1 |
| Non-Small-Cell Lung | 1 |
| Lung Cancer (NSCLC) | 1 |
| Small Cell Lung Cancer (SCLC) | 1 |
| Small Cell Lung Cancer | 1 |
| Small Cell Lung Cancer ( SCLC ) | 1 |
| Transformed Small Cell Lung Cancer | 1 |
| Intestinal Neoplasms | 1 |
| Gastrointestinal Neoplasms | 1 |
| Digestive System Neoplasms | 1 |
| Neoplasms by Site | 1 |
| Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma | 1 |
| Metastatic Gastric Cancer | 1 |
| Gastroesophageal Junction Cancer | 1 |
| Esophageal Adenocarcinoma | 1 |
| Urothelial Cancer | 1 |
| Advanced/Metastatic Urothelial Cancer | 1 |
| Urothelial Carcinoma | 1 |
| Advanced/Metastatic Non-Small Cell Lung Cancer | 1 |
| Carcinoma, Non-Small Cell Lung | 1 |
| Advanced Non-Small Cell Lung Cancer | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Carcinoma, Non-Small-Cell Lung (NSCLC) | 1 |
| Carcinoma, Hepatocellular | 1 |
| Hepatocellular Cancer | 1 |
| Hepatocellular Carcinoma | 1 |
| Unresectable Hepatocellular Carcinoma | 1 |
| Carcinoma, Renal Cell | 1 |
| Advanced Renal Cell Carcinoma | 1 |
| Renal Cancer | 1 |
| Renal Neoplasm | 1 |
| Lead sponsor | Trials |
|---|---|
| Pfizer | 10 |
| Register | PF-08634404 trials |
|---|---|
| Clinical trials in USA | 10 |
| Clinical trials in China | 9 |
| Clinical trials in India | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how PF-08634404 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists PF-08634404 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.